Skip to main content

Advertisement

Table 3 Summary of adverse events during triple antiplatelet therapy(significant effects are in bold).

From: Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis

Patients Intervention Major bleeding Minor bleeding Blood transfusions Thrombocytopenia
   Triple events/total Control events/total OR *(95% CI) Triple events/total Control events/total OR* (95% CI) Triple events/total Control events /total OR* (95% CI) Triple events/total Control events/total OR* (95% CI)
NSTE-ACS GP IIb/IIIa 34/1275 30/1274 1.15 (0.69-1.91) 46/1113 34/1111 1.37 (0.81-2.33) 45/1174 36/1173 1.27 (0.81-2.00) 8/1012 0/1010 17.1 (0.99-296.69)
STEMI GP IIb/IIIa 11/255 2/195 1.86 (0.43-8.17) 23/255 7/195 2.73 (1.15-6.46) 10/281 15/272 0.63 (0.28-1.44) 11/238 4/181 1.51 (0.48-4.71)
  Cilostazol 0/30 0/30           
Elective PCI GP IIb/IIIa 42/3314 34/3309 1.29 (0.70-2.36) 99/3314 62/3309 1.60 (1.16-2.21) 71/3264 40/3263 1.79 (1.14-2.79) 17/2269 0/2250 8.04 (1.82-35.59)
  Cilostazol 0/1054 1/1058 0.33 (0.01-8.24) 6/1054 7/1058 0.85(0.28-2.56)     1/450 2/450 0.62 (0.08-5.09)
  Clopidogrel 1/60 0/60 3.10 (0.12-79.29) 1/60 0/60 3.10 (0.12-79.23)       
  1. *Odds ratios were calculated from random effect models.
  2. NSTE-ACS, non-ST elevation acute coronary syndromes; STEMI, ST elevation myocardial infarction; PCI, percutaneous coronary intervention.